Advanced preclinical protocols, rigorous GLP standards, and validated botanical screening tailored for European regulatory compliance.
Navigating the nexus of Medicon Valley biotech excellence and high-capacity global laboratory infrastructure.
Denmark boasts one of the dense life-science clusters in Europe, centering on metabolic disorders, immunology, oncology, and microbiome-derived therapeutics. As local R&D costs climb and vivarium availability constricts, Danish drug developers require robust global CRO partners with institutional scalability.
Nordic ethical frameworks prioritize the 3Rs (Replacement, Reduction, Refinement). Our China research campuses incorporate digital micro-dosing, non-invasive imaging, and multi-endpoint telemetry to conform with Danish Animal Experiments Inspectorate (Dyreforsøgstilsynet) benchmarks.
All in vivo preclinical studies are designed to support Clinical Trial Applications (CTA) under the European Medicines Agency (EMA) and Danish Medicines Agency (Lægemiddelstyrelsen), featuring pristine raw data provenance and bilingual audit-ready documentation.
Combining world-class vivarium automation with seamless analytical integration to compress study timelines.
Our centralized animal testing facilities in Changsha utilize modern automated IVC (Individually Ventilated Cage) systems, robotic environmental control, and real-time physiological telemetry. This reduces observer-induced variability and yields hyper-reproducible pharmacokinetic (PK), pharmacodynamic (PD), and toxicological datasets for Danish biotech researchers.
Unlike fragmented CROs, our animal facilities sit adjacent to pilot-scale active botanical extraction, HPLC/HPTLC testing, and high-resolution mass spectrometry labs. This cohesive structure enables instant substance characterization, immediate re-synthesis of active fractions, and frictionless dose escalation assessments without international logistics bottlenecks.
How Nordic enterprises optimize drug pipeline expenditure without sacrificing rigorous scientific validity.
Complete regulatory toxicology modules including acute toxicity (LD50), 28-day and 90-day sub-chronic repeated dose studies, safety pharmacology (cardiovascular, respiratory, CNS), and OECD-compliant genotoxicity batteries (Ames test, micronucleus assay).
Specialized transgenic mouse and rat models covering diet-induced obesity (DIO), STZ-induced Type 1 and Type 2 diabetes, non-alcoholic steatohepatitis (NASH), rheumatoid arthritis, and xenograft tumor models optimized for biologics and phytochemical candidates.
We operate under bilateral Non-Disclosure Agreements governed by transparent international legal clauses. Full traceability, zero-leakage intellectual property protocols, and secure digital cloud vaults safeguard your molecular formulas and biological data assets.
Strategic advancements advancing animal model precision through 2026–2030.
Deployment of ultra-sensitive LC-MS/MS platforms combined with micro-sampling techniques to reduce the total number of subjects required while deriving dynamic systemic concentration metrics.
Establishment of Danish-collaborative humanized PBMC and CD34+ mice for targeted immuno-oncology, as well as germ-free animal colonies for complex botanical-gut axis validation.
Synthesizing historical empirical data from over 100,000 biological study batches to computationally predict organ toxicity profiles before initiating living animal protocols, maximizing 3Rs compliance.
Consult with our principal toxicologists and pharmacological study directors today. Receive customized protocol scopes, ethical validation frameworks, and turnaround estimates within 24 hours.
Everything you need to know about partnering with our China animal study facility.
Explore our complete suite of preclinical, clinical, and analytical research capabilities engineered for the global pharmaceutical sector.
